ImmuneOncia Therapeutics Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-27,363	-5,687	8,864	-3,492	-60,490
Depreciation & Amortization	890.41	1,051	1,031	1,081	1,026
Loss (Gain) From Sale of Assets	-	-	0.77	1.38	3.18
Stock-Based Compensation	409.46	981.9	1,311	3,991	1,948
Other Operating Activities	-269.92	-5,982	-19,648	-10,767	48,945
Change in Accounts Receivable	421.83	-410.83	622.65	-710.85	-
Change in Unearned Revenue	-	-	-	-4,952	6,884
Change in Other Net Operating Assets	3,136	-4,623	-518.09	-452.73	-292.68
Operating Cash Flow	-22,775	-14,670	-8,337	-15,301	-1,976
Capital Expenditures	-329.97	-86.87	-428.43	-36.21	-101.34
Sale (Purchase) of Intangibles	-137.74	-52.09	-	-52.4	-4.85
Investment in Securities	-12,100	1,900	-5,000	6,000	2,708
Other Investing Activities	-545.95	-32.6	96.71	-8.47	-840
Investing Cash Flow	-13,114	1,728	-5,332	5,903	1,762
Long-Term Debt Repaid	-51.87	-48.87	-103.65	-232.1	-210.93
Net Debt Issued (Repaid)	-51.87	-48.87	-103.65	-232.1	-210.93
Issuance of Common Stock	36,021	259	8,000	-	6,000
Other Financing Activities	-69.1	-3.18	-0	-	-
Financing Cash Flow	35,900	206.96	7,896	-232.1	24,289
Foreign Exchange Rate Adjustments	-	4.09	-	40.44	218.5
Miscellaneous Cash Flow Adjustments	-0	-	-0	-	-
Net Cash Flow	11.34	-12,731	-5,773	-9,590	24,293
Free Cash Flow	-23,105	-14,757	-8,766	-15,337	-2,078
Free Cash Flow Margin	-20776.54%	-2254.59%	-7968.93%	-198.32%	-5779.96%
Free Cash Flow Per Share	-329.32	-262.08	-167.13	-294.29	-44.72
Cash Interest Paid	5.12	6.93	-	-	-
Cash Income Tax Paid	355.61	-11.04	50.18	15.8	15.98
Levered Free Cash Flow	-13,443	-10,722	-4,331	-11,188	2,384
Unlevered Free Cash Flow	-13,440	-10,718	-4,329	-11,188	2,384
Change in Working Capital	3,558	-5,034	104.56	-6,116	6,591

Source: S&P Global Market Intelligence. Standard template. Financial Sources.